Kayne Anderson Rudnick Investment Management
ESPR

Kayne Anderson Rudnick Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,541
Closed -$453K – 325
2015
Q2 		$453K Buy
+5,541
New +$542K 0.01% 276

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ESPR Position: Q3 2015 in Review

Kayne Anderson Rudnick Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 5,541 shares — an estimated $453K sold.

Kayne Anderson Rudnick Investment Management first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $453K in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Kayne Anderson Rudnick Investment Management reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 5,541 Esperion Therapeutics shares in Q3 2015, an estimated $453K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Esperion Therapeutics position peaked at $453K in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q3 2015, filed 6 Nov 2015.